Charles River Laboratories International, Inc. Stock price
Equities
CRL
US1598641074
Biotechnology & Medical Research
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
193.39 USD | -1.32% | -2.12% | -11.25% |
Financials (USD)
Sales 2023 * | 4,135 M | Sales 2024 * | 4,352 M | Capitalization | 10 048 M |
---|---|---|---|---|---|
Net income 2023 * | 399 M | Net income 2024 * | 467 M | EV / Sales 2023 * | 2,96x |
Net Debt 2023 * | 2,196 M | Net Debt 2024 * | 1,773 M | EV / Sales 2024 * | 2,72x |
P/E ratio 2023 * | 25,6x | P/E ratio 2024 * | 22,1x | Employees | - |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 98.18% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | -1.32% | ||
1 week | -2.12% | ||
Current month | -1.32% | ||
1 month | -5.34% | ||
3 months | -7.32% | ||
6 months | -3.43% | ||
Current year | -11.25% |
1 week
191.00
198.90

1 month
191.00
213.04

Current year
181.22
262.00

1 year
181.22
262.00

3 years
181.22
460.21

5 years
95.58
460.21

10 years
44.12
460.21

Managers | Title | Age | Since |
---|---|---|---|
James Foster
CEO | Chief Executive Officer | 72 | 1991 |
Flavia Pease
DFI | Director of Finance/CFO | 50 | 2022 |
Matthew Daniel
CMP | Compliance Officer | - | 2010 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Foster
CHM | Chairman | 72 | 1999 |
Richard Wallman
BRD | Director/Board Member | 72 | 2011 |
C. Richard Reese
BRD | Director/Board Member | 77 | 2007 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.05% | 2 M$ | -4.17% | - | |
0.78% | 8 M$ | -9.98% |
Date | Price | Change | Volume |
---|---|---|---|
23-10-02 | 193.39 | -1.32% | 523,703 |
23-09-29 | 195.98 | +0.34% | 365,659 |
23-09-28 | 195.31 | +0.19% | 433,619 |
23-09-27 | 194.94 | +0.26% | 403,647 |
23-09-26 | 194.44 | -1.58% | 337,312 |
Delayed Quote Nyse, October 02, 2023 at 04:00 pm EDT
More quotes
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows:
- discovery and safety assessment services (59.5%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides;
- development of solutions used in drug manufacturing processes (21%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies;
- development and sale of research models and related services (19.5%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies.
Net sales break down by source of income between sales of services (77.8%) and sales of products (22.2%).
Net sales are distributed geographically as follows: the United States (54.6%), Europe (29.3%), Canada (9.6%), Asia/Pacific (6.3%) and other (0.2%).
Calendar
2023-10-31
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy

Mean consensus
BUY
Number of Analysts
16
Last Close Price
195.98USD
Average target price
238.64USD
Spread / Average Target
+21.77%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
-11.25% | 10 048 M $ | |
-5.43% | 168 M $ | |
0.00% | 54 M $ | |
-39.18% | 796 M $ | |
+22.70% | 897 M $ | |
-29.44% | 85 M $ | |
+87.39% | 1 777 M $ | |
-57.21% | 51 M $ | |
-.--% | 434 M $ | |
-65.52% | 213 M $ |